POINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? Yes

Damian G. Downey

doi:10.1016/j.chest.2021.05.070

POINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? Yes

Damian G. Downey^*

^*Corresponding author for this work

Research output: Contribution to journal › Editorial › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	18-20
Number of pages	3
Journal	Chest
Volume	161
Issue number	1
DOIs	https://doi.org/10.1016/j.chest.2021.05.070
Publication status	Published - 01 Jan 2022

Bibliographical note

Funding Information:
FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: D. G. D. has received honoraria and acted as a clinical trial principal investigator for Vertex Pharmaceuticals and Proteostasis Therapeutics.

Keywords

Administration, Inhalation
Adolescent
Adult
Age Distribution
Age Factors
Anti-Bacterial Agents/therapeutic use
Child
Child, Preschool
Chloride Channel Agonists/therapeutic use
Cystic Fibrosis/drug therapy
Diabetes Mellitus/drug therapy
Disease Management
Disease Progression
Female
Humans
Infant
Infant, Newborn
Male
Middle Aged
Patient Care Planning
Phenotype
Pseudomonas Infections/drug therapy
Young Adult

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.chest.2021.05.070Licence: Unspecified

Cite this

@article{4135b23a922f469abd93ab7be6d081ab,

title = "POINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? Yes",

keywords = "Administration, Inhalation, Adolescent, Adult, Age Distribution, Age Factors, Anti-Bacterial Agents/therapeutic use, Child, Child, Preschool, Chloride Channel Agonists/therapeutic use, Cystic Fibrosis/drug therapy, Diabetes Mellitus/drug therapy, Disease Management, Disease Progression, Female, Humans, Infant, Infant, Newborn, Male, Middle Aged, Patient Care Planning, Phenotype, Pseudomonas Infections/drug therapy, Young Adult",

author = "Downey, {Damian G.}",

note = "Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: D. G. D. has received honoraria and acted as a clinical trial principal investigator for Vertex Pharmaceuticals and Proteostasis Therapeutics.",

year = "2022",

month = jan,

day = "1",

doi = "10.1016/j.chest.2021.05.070",

language = "English",

volume = "161",

pages = "18--20",

journal = "Chest",

issn = "0012-3692",

publisher = "American College of Chest Physicians",

number = "1",

}

TY - JOUR

T1 - POINT: In the Era of Cystic Fibrosis Transmembrane Regulator Protein Modulator Therapy, Are the Treatment Goals for Adults Now Different From Those for Children With Cystic Fibrosis? Yes

AU - Downey, Damian G.

N1 - Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: D. G. D. has received honoraria and acted as a clinical trial principal investigator for Vertex Pharmaceuticals and Proteostasis Therapeutics.

PY - 2022/1/1

Y1 - 2022/1/1

KW - Administration, Inhalation

KW - Adolescent

KW - Adult

KW - Age Distribution

KW - Age Factors

KW - Anti-Bacterial Agents/therapeutic use

KW - Child

KW - Child, Preschool

KW - Chloride Channel Agonists/therapeutic use

KW - Cystic Fibrosis/drug therapy

KW - Diabetes Mellitus/drug therapy

KW - Disease Management

KW - Disease Progression

KW - Female

KW - Humans

KW - Infant

KW - Infant, Newborn

KW - Male

KW - Middle Aged

KW - Patient Care Planning

KW - Phenotype

KW - Pseudomonas Infections/drug therapy

KW - Young Adult

U2 - 10.1016/j.chest.2021.05.070

DO - 10.1016/j.chest.2021.05.070

M3 - Editorial

C2 - 35000701

AN - SCOPUS:85121606683

SN - 0012-3692

VL - 161

SP - 18

EP - 20

JO - Chest

JF - Chest

IS - 1

ER -